309 related articles for article (PubMed ID: 37400647)
21. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
[TBL] [Abstract][Full Text] [Related]
22. The β-Lactams Strike Back: Ceftazidime-Avibactam.
Zasowski EJ; Rybak JM; Rybak MJ
Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
[TBL] [Abstract][Full Text] [Related]
23. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
24. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
Karaiskos I; Galani I; Souli M; Giamarellou H
Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
[TBL] [Abstract][Full Text] [Related]
25. Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).
Boattini M; Comini S; Bianco G; Iannaccone M; Casale R; Cavallo R; Costa C
J Chemother; 2023 May; 35(3):198-204. PubMed ID: 35731718
[TBL] [Abstract][Full Text] [Related]
26. Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
Tamma PD; Hsu AJ
J Pediatric Infect Dis Soc; 2019 Jul; 8(3):251-260. PubMed ID: 30793757
[TBL] [Abstract][Full Text] [Related]
27. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.
Bush K
Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989
[TBL] [Abstract][Full Text] [Related]
28. Imipenem-Relebactam Susceptibility in
Hernández-García M; García-Castillo M; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Cruz H; Chaves C; Duarte J; Pássaro L; Díaz-Regañón J; Cantón R
Microbiol Spectr; 2022 Oct; 10(5):e0292722. PubMed ID: 36043877
[TBL] [Abstract][Full Text] [Related]
29. [New β‑lactam antibiotics and β‑lactamase inhibitors against multidrug-resistant Gram-negative bacteria].
Mischnik A; Lübbert C; Mutters NT
Internist (Berl); 2018 Dec; 59(12):1335-1343. PubMed ID: 30264191
[TBL] [Abstract][Full Text] [Related]
30. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies.
Lodise TP; Bassetti M; Ferrer R; Naas T; Niki Y; Paterson DL; Zeitlinger M; Echols R
Expert Rev Anti Infect Ther; 2022 May; 20(5):707-719. PubMed ID: 34937518
[TBL] [Abstract][Full Text] [Related]
31. [Chinese expert consensus on the management of lower respiratory tract infections of
Pulmonary Infection Assembly of Chinese Thoracic Society
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Aug; 45(8):739-752. PubMed ID: 35927044
[TBL] [Abstract][Full Text] [Related]
32. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
Wenzler E; Scoble PJ
Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557
[TBL] [Abstract][Full Text] [Related]
33. Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates.
Kontou A; Kourti M; Iosifidis E; Sarafidis K; Roilides E
Antibiotics (Basel); 2023 Jun; 12(6):. PubMed ID: 37370391
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation.
Bakdach D; Elajez R; Bakdach AR; Awaisu A; De Pascale G; Ait Hssain A
J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498473
[TBL] [Abstract][Full Text] [Related]
35. New perspectives in the antibiotic treatment of mechanically ventilated patients with infections from Gram-negatives.
Karvouniaris M; Pontikis K; Nitsotolis T; Poulakou G
Expert Rev Anti Infect Ther; 2021 Jul; 19(7):825-844. PubMed ID: 33270485
[No Abstract] [Full Text] [Related]
36. The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections.
Bouza E
J Antimicrob Chemother; 2021 Nov; 76(Suppl 4):iv38-iv45. PubMed ID: 34849998
[TBL] [Abstract][Full Text] [Related]
37. Carbapenemase producing
Karaiskos I; Galani I; Papoutsaki V; Galani L; Giamarellou H
Expert Rev Anti Infect Ther; 2022 Jan; 20(1):53-69. PubMed ID: 34033499
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and
Cruz-López F; Martínez-Meléndez A; Morfin-Otero R; Rodriguez-Noriega E; Maldonado-Garza HJ; Garza-González E
Front Cell Infect Microbiol; 2022; 12():884365. PubMed ID: 35669117
[TBL] [Abstract][Full Text] [Related]
39. New antibiotics for Gram-negative pneumonia.
Bassetti M; Magnè F; Giacobbe DR; Bini L; Vena A
Eur Respir Rev; 2022 Dec; 31(166):. PubMed ID: 36543346
[TBL] [Abstract][Full Text] [Related]
40. Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective.
Giacobbe DR; Roberts JA; Abdul-Aziz MH; de Montmollin E; Timsit JF; Bassetti M
Expert Rev Anti Infect Ther; 2022 Jul; 20(7):963-979. PubMed ID: 35385681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
